Tandem Diabetes Care (BSP:T2ND34) 1-Year Sharpe Ratio: N/A (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T2ND34 Tandem Diabetes Care Inc BSP:T2ND34
49 GF Score
Price R$5.98
GF Value R$8.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-22), Tandem Diabetes Care's 1-Year Sharpe Ratio is Not available.

Tandem Diabetes Care  (BSP:T2ND34) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Tandem Diabetes Care 1-Year Sharpe Ratio Related Terms

BSP:T2ND34 vs CNMD, ATEC, ENOV: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tandem Diabetes Care 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's 1-Year Sharpe Ratio falls into.


BSP:T2ND34
49GF Score
Tandem Diabetes Care Inc BSP:T2ND34
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of R$5.98 is trading 28.5% below its estimated GF Value™ of R$8.36. GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.

Key valuation signals for BSP:T2ND34:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: R$8.36 vs. price of R$5.98 (28.5% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Other Exchanges TNDM:USA0M0F:UKTD5A:Germany
Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
49GF Score

Get the complete analysis for BSP:T2ND34

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.98
Price
R$8.36
GF Value